ALTIMMUNE INC (ALT)
Health Care · Clinical-stage immunotherapy · NASDAQ
Pre-revenue clinical-stage immunotherapy biotech developing pemvidutide and other novel candidates with no approved products yet commercialized.
What ALTIMMUNE INC does
Altimmune is a late-stage clinical biotechnology company focused on developing novel immunotherapeutic product candidates. The company's lead candidate, pemvidutide, has completed Phase 2 development with Phase 3 clinical trials planned. Altimmune has incurred significant net losses since inception and has not yet generated any product revenues or received regulatory approvals for commercialization.
Themes: ["immunotherapy / clinical development","obesity / metabolic disease","biotech drug development"]
Fundamentals
- Price$3.12 as of 2026-07-09 close
- Market cap$608M as of 2026-07-10
- 1-year return-34.2% as of 2026-07-09 close
- Net margin-214861.0% as of 2026-07-10
- Gross margin+100.5% as of 2026-07-10
- ROE-42.6% as of 2026-07-10
- Debt / equity0.12 as of 2026-07-10
- Revenue growth (YoY)+80.0% as of 2026-07-10
- Beta0.13 as of 2026-07-10
Key risks (from latest filing)
["Company has incurred significant losses since inception ($649.5M accumulated deficit as of Dec 31, 2025) and may never achieve profitability; no regulatory approvals or product revenues to date.","Lead candidate pemvidutide remains in clinical development with Phase 3 trials planned; regulatory approval and commercial success are uncertain and could take years or never occur.","Continued substantial operating losses anticipated; company depends on successful completion of clinical trials, regulatory approval, and ability to manufacture, market and commercialize products."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.